We use cookies to help provide you with the best possible online experience. By using this site, you agree that we may store and access cookies on your device. You can find out more about how to set your own preferences here.
Accept cookies

E. faecium SF68®: a model for efficacy & safety for Pharmaceutical Probiotics

April 19 2018

Cerbios-Pharma SA (from now on “Cerbios”) is pleased to announce the publication of a comprehensive review on its proprietary Probiotic Active Ingredient E. faecium SF68® (SF68®).

In an article, published in the Scientific Journal “Beneficial Microbes”, extensive information is provided on the efficacy and safety of SF68® supported by well established scientific and surveillance data.

Exactly 50 years after the discovery of the probiotic strain, this review provides an overview on the huge amount of scientific information available regarding efficacy and safety of our Probiotic.

„This article is in line with our experience of over thirty years distribution to patients in different markets where SF68® has gained importance thanks to its beneficial effects for the prevention and treatment of gastrointestinal disorders without any adverse event“, confirms Gabriel Haering, CEO of Cerbios.

In fact, SF68® has been used since decades both for human and animal health applications and is considered as one of the best characterised probiotic with respect to efficacy and safety with an exceptionally long history of safe use in probiotic therapy.

The review is entitled “Enterococcus faecium SF68® as a model for Efficacy and Safety evaluation of pharmaceutical probiotics”. The authors are experts in the field of probiotics with profound know-how on Enterococci and, in particular, on SF68®. Among them are the renowned scientists Prof. Wilhelm Holzapfel and Prof. Bruno Pot.

To see the abstract in Beneficial Microbes click here

The full original publication is available at this link.

About SF68®
SF68® is a probiotic active ingredient of pharmaceutical quality produced by Cerbios-Pharma SA and is contained in pharmaceutical probiotics such as Bioflorin®, Newflora®, Neoflor®, Diaflor® and Ventrux®.
It is approved as a pharmaceutical probiotic by the health authorities of different countries, starting from Switzerland in 1979.
Besides its application as pharmaceutical probiotic it is approved by EFSA under the name of the strain deposit E. faecium NCIMB 10415 as a ”gut flora stabiliser” for various animal categories.

About Cerbios-Pharma SA

Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide.

Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAIs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.

Cerbios provides full CMC support to its world-wide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
Download file (File size - 0.18)
[[ getItemTitle(currentIndex) ]]